Jyoti Baharani
Overview
Explore the profile of Jyoti Baharani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
369
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hamer R, Hameed A, Damery S, Jenkins K, Dasgupta I, Baharani J
Semin Dial
. 2023 Jun;
36(5):407-413.
PMID: 37272333
Background: In the United Kingdom, over 80% of end-stage kidney disease patients receive in-center hemodialysis. We conducted a survey of UK renal healthcare workers on their preferred dialysis modality if...
12.
Zhang Y, Baharani J
Hemodial Int
. 2023 Apr;
27(3):224-230.
PMID: 37010138
Pre-dialysis education forms a crucial part of dialysis preparation. Acute start dialysis patients often commence and remain on in-center hemodialysis (ICHD) without the benefit of an informed decision making process...
13.
Soran V, Rezai F, Nirmal R, Nash K, Karama M, Baharani J, et al.
Future Healthc J
. 2022 Oct;
9(Suppl 2):45.
PMID: 36310973
No abstract available.
14.
Law S, Arnold J, Rauf M, Heptinstall L, Gilbertson J, Rowczenio D, et al.
Am J Kidney Dis
. 2022 Oct;
81(5):606-610.
PMID: 36228827
Inotersen is an antisense oligonucleotide inhibitor licensed for the treatment of polyneuropathy complicating hereditary transthyretin amyloidosis (ATTRv). Nephrotoxicity has been reported with inotersen, including progression to kidney failure. We describe...
15.
Balson L, Stevenson T, Baharani J
J Vasc Access
. 2022 Jun;
25(1):239-243.
PMID: 35761791
Background: Haemodialysis remains the most common modality of renal replacement therapy. National and international guidelines continue to promote arteriovenous fistulas or grafts as the preferred vascular access for haemodialysis, given...
16.
Selvaskandan H, Baharani J, Hamer R
Clin Exp Nephrol
. 2022 May;
26(9):886-897.
PMID: 35524893
Background: The United Kingdom offers a standardised training program for nephrology fellows. However, local training opportunities vary resulting in mismatches between trainee interests and accessible opportunities. This may impact trainee...
17.
Shah N, Cole A, McCarthy K, Baharani J
Blood Purif
. 2022 Apr;
51(12):1022-1030.
PMID: 35477096
Introduction: Peritoneal dialysis (PD) remains underutilised in the West. The proportion of patients in the UK starting renal replacement therapy (RRT) with PD fell from 7.2% in 2011 to 6.0%...
18.
Ewart C, Baharani J, Wilkie M, Thomas N
J Ren Care
. 2022 Mar;
48(3):143-153.
PMID: 35338610
Background: The coronavirus disease 2019 (COVID-19) pandemic resulted in a rapid and sometimes chaotic change in how clinical care was delivered for people living with kidney disease, with increased reliance...
19.
Balson L, Baharani J
Clin Med (Lond)
. 2021 Sep;
21(5):e556-e558.
PMID: 34507945
While all patients with chronic disease have undoubtedly been affected by the ongoing SARS-CoV-2 (COVID-19) pandemic, individuals with end-stage renal failure have suffered significant excess morbidity and mortality. Patients on...
20.
Tabinor M, Crowley L, Godlee A, Flanagan D, Rashid R, Baharani J, et al.
Hemodial Int
. 2021 Aug;
26(1):83-93.
PMID: 34378315
Introduction: Coronavirus disease 2019 (COVID-19) adversely affects patients who are older, multimorbid, and from Black, Asian or minority ethnicities (BAME). We assessed whether being from BAME is independently associated with...